Streetbeat News

ICVX

Icosavax Inc

Employees

61

Industry

Biological Product (except Diagnostic) Manufacturing

icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. the company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the institute for protein design at the university of washington. icosavax is located in seattle.

Open

15.40

Mkt cap

769M

Volume

8.6M

High

15.44

P/E Ratio

-6.96

52-wk high

16.11

Low

15.28

Div yield

N/A

52-wk low

4.75

Icosavax, Inc. (NASDAQ:ICVX) announced positive interim results from its Phase 2 clinical trial for IVX-A12, a vaccine candidate targeting RSV and hMPV in older adults. The company's VLP platform technology focuses on developing vaccines for life-threatening respiratory diseases, aiming for pan-respiratory vaccines for older adults.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 7:24 am

AstraZeneca is set to acquire Icosavax for $15 per share in cash, with an additional contingent value right of up to $5 per share based on regulatory and sales milestones. The deal values Icosavax at approximately $838 million upfront, a 43% premium over its closing price on December 11, 2023, and could reach $1.1 billion in total value, representing a 91% premium if all conditions are met.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 7:16 am

Icosavax's stock (ICVX) is trading higher following Guggenheim's initiation of coverage with a Buy rating and a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:17 pm

Ross Stores, Inc. (NASDAQ:ROST) reported strong third-quarter earnings, beating estimates with $1.33 per share and revenue of $4.92 billion, leading to an 8.8% stock surge. The company also raised its FY23 EPS guidance. Other stocks like The Gap, Inc. (NYSE:GPS), Twist Bioscience Corporation (NASDAQ:TWST), and several others also moved higher on Friday after reporting positive financial results or receiving favorable analyst ratings.

Portfolio Pulse from Lisa Levin

November 17, 2023 | 4:02 pm

Guggenheim analyst Seamus Fernandez has initiated coverage on Icosavax (NASDAQ:ICVX) with a Buy rating and set a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 1:14 pm

Shapeways Holdings, Inc. (SHPW) shares dropped by approximately 20% following the release of disappointing financial results, with an adjusted loss per share and quarterly sales both missing market expectations. Other stocks experienced significant movement in Wednesday's mid-day session, with various companies reporting financial results, FDA designations, and potential acquisition interest.

Portfolio Pulse from Lisa Levin

November 15, 2023 | 7:04 pm

Icosavax's stock price has increased following the announcement of their third-quarter earnings per share (EPS) results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 5:44 pm

Target Corporation reported better-than-expected Q3 FY23 results with sales of $25.398 billion and adjusted EPS of $2.10, causing its shares to rise 18.2%. Other stocks also moved higher, including AST SpaceMobile, Arcturus Therapeutics, CorMedix, Gyre Therapeutics, Dada Nexus, Icosavax, iHeartMedia, V.F. Corporation, Wolfspeed, Sigma Lithium, Chegg, Catalent, Vipshop Holdings, Tencent Music Entertainment, Kohl's, Macy's, Sirius XM Holdings, Expedia Group, Crocs, Tripadvisor, and American Eagle Outfitters, following positive earnings reports, upgrades, and partnership announcements.

Portfolio Pulse from Lisa Levin

November 15, 2023 | 4:08 pm

Icosavax (NASDAQ:ICVX) reported a Q3 EPS loss of $(0.44), surpassing the analyst consensus estimate of $(0.57) by 22.81%. The reported loss shows a 20% improvement from the $(0.55) per share loss in the same quarter of the previous year.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 9:36 pm

Oppenheimer analyst Hartaj Singh has reiterated an 'Outperform' rating on Icosavax (NASDAQ:ICVX) and maintained a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.